IMPORTANCE OF THE FIELD: Inhalational anthrax is a disease with a high lethality 
potential and current therapeutic interventions with antibiotics to manage the 
bacteraemia might not always be fully effective. Blocking the activity of the 
toxins with raxibacumab, a fully-human mAb directed against the protective 
antigen of Bacillus anthracis, may serve as an adjunct treatment. The existing 
ones are aimed at preventing post-exposure bacteraemia but might not be always 
fully protective. Therefore, more specific 'therapies' are needed and the 
protective antigen of B. anthracis might be targeted effectively with 
raxibacumab, which is a blocking human mAb. AREAS COVERED IN THIS PAPER: To 
discuss the results of experimental and human studies evaluating raxibacumab for 
inhalational anthrax.
WHAT THE READER WILL GAIN: Raxibacumab was efficacious prophylactically after 
exposure and therapeutically before exposure in rabbit and monkey animal models 
of inhalational anthrax and exhibited good safety and pharmacokinetic profiles 
in healthy humans.
TAKE HOME MESSAGE: Raxibacumab is a promising prophylactic and therapeutic for 
inhalational anthrax.